BY THE DIGITAL HEALTH LEADERS
FOR THE DIGITAL HEALTH COMMUNITY
User Icon
Sign Up
User Icon User
Exclusive
scalehealthtech Realize your Healthcare’s Digital Transformation journey with ScaleHealthTech Learn More

Venus Remedies Gains Approval for Bleomycin 15,000 IU in the UK

Written by : Dr. Aishwarya Sarthe

October 27, 2023

Category Img

Additionally, it proves invaluable in addressing severe lymph node cancers like Hodgkin's disease and non-Hodgkin's lymphoma of intermediate and high malignancy.

Haryana-based Venus Remedies has received market approval for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion in the United Kingdom through its subsidiary, Venus Pharma GmbH, based in Germany.

This medication, which features bleomycin sulphate as its active ingredient, belongs to the cytostatic drug category and is designed to combat cancer.

Bleomycin 15,000 IU is a versatile treatment with applications in various medical scenarios, including managing squamous cell carcinomas in regions such as the head and neck, cervix, and external genitalia.

Additionally, it proves invaluable in addressing severe lymph node cancers like Hodgkin's disease and non-Hodgkin's lymphoma of intermediate and high malignancy. It has also shown efficacy in treating testicular cancer and conditions involving fluid accumulation in the lungs, often associated with cancer.

Saransh Chaudhary, CEO of Venus Medicine Research Center (VMRC), said, “The UK's market authorisation for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion is a significant step towards realising this mission. We remain dedicated to enhancing healthcare solutions and are committed to pursuing additional authorisations to reach even more needy patients."

This medication can be administered as a standalone treatment or combined with other cancer drugs and radiotherapy. Its approval in multiple countries globally highlights its effectiveness in cancer treatment.

Ashutosh Jain, CEO of Venus Pharma GmbH, noted that obtaining market approval from MHRA enables the company to play a pivotal role in advancing cancer care and improving the quality of life for patients facing this challenging disease.

Venus Remedies claims to hold a total of 15 Market Authorisations (MA) for Bleomycin products worldwide. They have also submitted 16 additional applications to Ministries of Health in various regions as part of their commitment to extending the reach of this vital medication.

Venus Remedies, established in 1989 in Haryana, is a global pharmaceutical company with a strong focus on research and development. Operating in 70 countries, the company boasts a portfolio of more than 500 Marketing Authorizations from regulated and emerging markets.

In other notable developments, Venus Remedies recently launched Elores, a novel antibiotic formulation in Ecuador, South America, as part of their ongoing efforts to combat multidrug-resistant infections.

Additionally, in September, Venus Remedies expanded its oncology portfolio in South Eastern Europe, securing 511 marketing approvals for its oncology products across 66 countries, demonstrating its commitment to enhancing global healthcare.

More from this Author

DHN

POPULAR CATEGORIES

WEEKLY POPULAR POSTS

ABOUT US

Digital Health News ( DHN) is India’s first dedicated digital health news platform launched by Industry recognized HealthTech Leaders. DHN Is Industry’s Leading Source Of HealthTech Business, Insights, Trends And Policy News.

DHN Provides In-Depth Data Analysis And Covers Most Impactful News As They Happen Across Entire Ecosystem Including Emerging Technology Trends And Innovations, Digital Health Startups, Hospitals, Health Insurance, Govt. Agencies & Policies, Pharmaceuticals And Biotech.

CONTACT US

DHN MEDIA INDIA PVT. LTD. 501, Fifth Floor, Pegasus Tower,
Sector-68, Noida

Email: info@digitalhealthnews.com

Call us: +91 99904 75326

© Copyrights 2024 DHN MEDIA INDIA PVT. LTD. All Rights Reserved, Terms & Conditions, Privacy Policy and Refund/Cancellation Policy

© Digital Health News 2024